{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Milwaukee&page=88&state=Wisconsin", "query": { "state": "Wisconsin", "city": "Milwaukee", "page": 88 }, "page_size": 10 }, "pagination": { "page": 88, "page_size": 10, "total_count": 5354, "total_pages": 536, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Milwaukee&page=89&state=Wisconsin&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Milwaukee&page=87&state=Wisconsin&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-05T12:12:19.545Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03327857", "title": "Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease or Treatment-refractory Acute Graft-versus-host Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Steroid-refractory Acute Graft-versus-Host Disease", "Treatment-refractory Acute Graft-versus-Host Disease" ], "interventions": [ { "name": "Neihulizumab (ALTB-168)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AltruBio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 37, "start_date": "2018-05-31", "completion_date": "2022-12-31", "has_results": false, "last_update_posted_date": "2023-01-19", "last_synced_at": "2026-11-05T12:12:19.545Z", "location_count": 13, "location_summary": "Duarte, California • Los Angeles, California • Miami, Florida + 10 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03327857" }, { "nct_id": "NCT00279981", "title": "TRENDS: A Prospective Study of the Clinical Significance of Atrial Arrhythmias Detected by Implanted Device Diagnostics", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Atrial Fibrillation", "Stroke", "Heart Failure" ], "interventions": [ { "name": "Diagnostic", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Medtronic Cardiac Rhythm and Heart Failure", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3100, "start_date": "2003-11", "completion_date": "2007-06", "has_results": false, "last_update_posted_date": "2008-12-11", "last_synced_at": "2026-11-05T12:12:19.545Z", "location_count": 92, "location_summary": "Mesa, Arizona • Tucson, Arizona • Fountain Valley, California + 89 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Mission Viejo", "state": "California" }, { "city": "Modesto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00279981" }, { "nct_id": "NCT04263337", "title": "NFL LONG Prospective Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Concussion, Brain" ], "interventions": [ { "name": "[11C] PiB", "type": "DRUG" }, { "name": "[18F] PBR111", "type": "DRUG" }, { "name": "[18F] Flortaucipir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": "70 Years", "sex": "MALE", "summary": "50 Years to 70 Years · Male only" }, "enrollment_count": 250, "start_date": "2020-03-12", "completion_date": "2028-08", "has_results": false, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-11-05T12:12:19.545Z", "location_count": 3, "location_summary": "Waltham, Massachusetts • Chapel Hill, North Carolina • Milwaukee, Wisconsin", "locations": [ { "city": "Waltham", "state": "Massachusetts" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04263337" }, { "nct_id": "NCT00032357", "title": "Does the Reduction of Total Body Iron Storage (TBIS) Alter Mortality in a Population of Patients With Advanced PVD?", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atherosclerosis", "Intermittent Claudication", "Peripheral Vascular Diseases" ], "interventions": [ { "name": "Ferritin reduction to 25 ng/ml by phlebotomy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "US Department of Veterans Affairs", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 1277, "start_date": "1999-05", "completion_date": "2005-09", "has_results": false, "last_update_posted_date": "2013-01-21", "last_synced_at": "2026-11-05T12:12:19.545Z", "location_count": 23, "location_summary": "Birmingham, Alabama • No. Little Rock, Arkansas • Long Beach, California + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "No. Little Rock", "state": "Arkansas" }, { "city": "Long Beach", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "West Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00032357" }, { "nct_id": "NCT03651128", "title": "Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "bb2121", "type": "BIOLOGICAL" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Ixazomib", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Elotuzumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 386, "start_date": "2019-04-16", "completion_date": "2026-04-13", "has_results": false, "last_update_posted_date": "2026-06-22", "last_synced_at": "2026-11-05T12:12:19.545Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03651128" }, { "nct_id": "NCT03266692", "title": "Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma", "Multiple Myeloma in Relapse", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "ACTR087", "type": "BIOLOGICAL" }, { "name": "SEA-BCMA", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Cogent Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 15, "start_date": "2018-02-22", "completion_date": "2019-10-01", "has_results": false, "last_update_posted_date": "2020-03-30", "last_synced_at": "2026-11-05T12:12:19.545Z", "location_count": 7, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Indianapolis, Indiana + 4 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03266692" }, { "nct_id": "NCT02202434", "title": "Safety and Efficacy Study of Lotus Valve for Transcatheter Aortic Valve Replacement", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Aortic Stenosis" ], "interventions": [ { "name": "Lotus Valve System", "type": "DEVICE" }, { "name": "CoreValve/Evolut R Transcatheter Aortic Valve Replacement System", "type": "DEVICE" }, { "name": "LOTUS Edge Valve System", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Boston Scientific Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1425, "start_date": "2014-09-22", "completion_date": "2021-05-21", "has_results": true, "last_update_posted_date": "2021-12-17", "last_synced_at": "2026-11-05T12:12:19.545Z", "location_count": 49, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 40 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02202434" }, { "nct_id": "NCT05950464", "title": "Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Endometrial Carcinoma", "Recurrent Endometrial Clear Cell Adenocarcinoma", "Recurrent Endometrial Endometrioid Adenocarcinoma", "Recurrent Endometrial Low Grade Endometrioid Adenocarcinoma", "Recurrent Ovarian Clear Cell Adenocarcinoma", "Recurrent Ovarian Endometrioid Adenocarcinoma", "Recurrent Ovarian High Grade Serous Adenocarcinoma", "Recurrent Ovarian Low Grade Endometrioid Adenocarcinoma", "Recurrent Platinum-Resistant Ovarian Carcinoma" ], "interventions": [ { "name": "BET Bromodomain Inhibitor ZEN-3694", "type": "DRUG" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Tuvusertib", "type": "DRUG" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 65, "start_date": "2023-12-18", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-10-27", "last_synced_at": "2026-11-05T12:12:19.545Z", "location_count": 14, "location_summary": "Augusta, Georgia • Chicago, Illinois • Iowa City, Iowa + 8 more", "locations": [ { "city": "Augusta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT05950464" }, { "nct_id": "NCT02505945", "title": "The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "GERD Gastroesophageal Reflux Disease" ], "interventions": [ { "name": "Omeprazole", "type": "DRUG" }, { "name": "LINX Reflux Management System", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Torax Medical Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 152, "start_date": "2015-06", "completion_date": "2018-08", "has_results": true, "last_update_posted_date": "2019-01-07", "last_synced_at": "2026-11-05T12:12:19.545Z", "location_count": 21, "location_summary": "Mobile, Alabama • Heber Springs, Arkansas • Los Angeles, California + 18 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Heber Springs", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Englewood", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02505945" }, { "nct_id": "NCT05255107", "title": "Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Keratitis", "Corneal Ulcer" ], "interventions": [ { "name": "Standard of Care Therapy + CXL + Riboflavin 0.23% L Solution", "type": "COMBINATION_PRODUCT" }, { "name": "Standard of Care Therapy + Sham CXL + Artificial Tears", "type": "OTHER" } ], "intervention_types": [ "COMBINATION_PRODUCT", "OTHER" ], "sponsor": "Peschke GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 468, "start_date": "2022-03-14", "completion_date": "2024-02-24", "has_results": false, "last_update_posted_date": "2022-10-28", "last_synced_at": "2026-11-05T12:12:19.545Z", "location_count": 12, "location_summary": "Littleton, Colorado • Fort Myers, Florida • Tampa, Florida + 9 more", "locations": [ { "city": "Littleton", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Teaneck", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05255107" } ] }